These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 29096154)

  • 21. Efficacy and Safety of Direct Oral Anticoagulants in Elderly Patients With Atrial Fibrillation: A Network Meta-Analysis.
    Deng K; Cheng J; Rao S; Xu H; Li L; Gao Y
    Front Med (Lausanne); 2020; 7():107. PubMed ID: 32318577
    [No Abstract]   [Full Text] [Related]  

  • 22. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal function in atrial fibrillation patients switched from warfarin to a direct oral anticoagulant.
    Minhas AS; Jiang Q; Gu X; Haymart B; Kline-Rogers E; Almany S; Kozlowski J; Krol GD; Kaatz S; Froehlich JB; Barnes GD
    J Thromb Thrombolysis; 2016 Nov; 42(4):566-72. PubMed ID: 27217043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can Direct Oral Anticoagulants Be Used for Stroke Prevention Among Patients with Valvular Atrial Fibrillation?
    Anderson SL; Marrs JC
    Curr Cardiol Rep; 2019 Aug; 21(10):118. PubMed ID: 31473836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin in Patients With Chronic Kidney Disease and Atrial Fibrillation.
    Makani A; Saba S; Jain SK; Bhonsale A; Sharbaugh MS; Thoma F; Wang Y; Marroquin OC; Lee JS; Estes NAM; Mulukutla SR
    Am J Cardiol; 2020 Jan; 125(2):210-214. PubMed ID: 31780073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients.
    Capodanno D; Capranzano P; Giacchi G; Calvi V; Tamburino C
    Int J Cardiol; 2013 Aug; 167(4):1237-41. PubMed ID: 22494863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
    Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indirect Comparison of Novel Oral Anticoagulants in Women with Nonvalvular Atrial Fibrillation.
    Moseley A; Doukky R; Williams KA; Jaffer AK; Volgman AS
    J Womens Health (Larchmt); 2017 Mar; 26(3):214-221. PubMed ID: 27870603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New direct oral oral anticoagulants (DOACs) - indications of DOACs].
    Darius H
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2014 Mar; 49(3):182-90; quiz 191. PubMed ID: 24711238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apixaban: Effective and Safe in Preventing Thromboembolic Events in Patients with Atrial Fibrillation and Renal Failure.
    Cortese F; Scicchitano P; Gesualdo M; Ricci G; Carbonara S; Franchini C; Pia Schiavone BI; Corbo F; Ciccone MM
    Curr Med Chem; 2017 Nov; 24(34):3813-3827. PubMed ID: 28820069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015.
    Kjerpeseth LJ; Ellekjær H; Selmer R; Ariansen I; Furu K; Skovlund E
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1417-1425. PubMed ID: 28735494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Anticoagulant therapy in patients with atrial fibrillation and reduced kidney function of diabetic and non-diabetic etiologies].
    Sokolova AA; Daabul IS; Tsarev IL; Napalkov DA; Fomin VV
    Ter Arkh; 2017; 89(12):10-14. PubMed ID: 29411755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gender Differences in Efficacy and Safety of Direct Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Network Meta-analysis.
    Raccah BH; Perlman A; Zwas DR; Hochberg-Klein S; Masarwa R; Muszkat M; Matok I
    Ann Pharmacother; 2018 Nov; 52(11):1135-1142. PubMed ID: 29681165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discrepancies between the use of MDRD-4 IDMS and CKD-EPI equations, instead of the Cockcroft-Gault equation, in the determination of the dosage of direct oral anticoagulants in patients with non-valvular atrial fibrillation.
    Pérez Cabeza AI; Chinchurreta Capote PA; González Correa JA; Ruiz Mateas F; Rosas Cervantes G; Rivas Ruiz F; Valle Alberca A; Bravo Marqués R
    Med Clin (Barc); 2018 Feb; 150(3):85-91. PubMed ID: 28739270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
    Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
    Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.